In Depth 3 Jun 2025 How biotechs are developing novel treatments to tackle high cholesterol …with patients likely to have access in the coming years to a variety of different treatments that can help them reduce one of the main risk factors for cardiovascular events…. June 3, 2025 - 10 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 24 Jan 2024 A new chapter in cell therapy: engineered B cells reach the clinic for the first time …mechanism. Immusoft also uses a non-viral delivery system. Ainsworth noted that this removes the need for immunosuppression associated with viral delivery. “Some clinical trials have shown numerous serious adverse events… January 24, 2024 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 31 Jul 2018 Israeli Crohn’s Disease Drug Rakes in Positive Phase III Results …gut bacteria to find treatments for Crohn’s disease. For example, the French biotech Enterome is developing a small molecule drug that prevents bacteria in the gut from releasing inflammation-causing molecules…. July 31, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
Podcast 12 May 2023 Beyond Biotech podcast 45: International MPS Awareness Day …Society in the U.S., mucopolysaccharidosis (MPS) and mucolipidosis (ML) are genetic lysosomal storage diseases (LSD) caused by the body’s inability to produce specific enzymes. The missing or insufficient enzyme prevents… May 12, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 19 Jun 2023 Gene therapy: a promising solution for sickle cell disease …have a history of vaso-occlusive events. Lovo-cel is designed to add functional copies of a modified form of the beta-globin gene into a patient’s own hematopoietic (blood) stem cells, which… June 19, 2023 - 6 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 13 Dec 2017 How Biotech Could Change Your Christmas Dinner …fish and caviar. But aren’t vegetables healthy enough already? Not quite. Calyxt’s gene-edited potatoes have had an enzyme removed that would degrade starch. This prevents the formation of carcinogenic acrylamide… December 13, 2017 - 6 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
In Depth 15 Feb 2024 Biogen: how is the biotech giant pivoting from a failed Alzheimer’s drug? …and the safety concerns alive even though there wasn’t sufficient evidence to link those events to the drug. Adding to its troubles, Biogen withdrew its application for marketing authorization of… February 15, 2024 - 11 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Opinion 17 Nov 2025 Precision psychiatry is the future of mental healthcare …serves on Barnard’s Leadership Council at Athena Center. She is a presenter at national biotech industry events, has been featured in numerous publications, and frequently speaks on issues pertaining to… November 17, 2025 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
In Depth 1 Feb 2023 How can cancer care be improved? …works in a subset of patients. By being able to select and monitor patients to determine when and if they should receive cancer immunotherapy and to highlight adverse events more… February 1, 2023 - 7 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 26 Sep 2017 British Biotech Pockets Massive Series C for its CAR-T Cancer Therapies …the infrastructure to rapidly bring a CAR-T cell therapy to the market. Autolus prevents cancer cells from escaping the immune system by reprogramming T cell receptors (TCRs) using powerful chimeric… September 26, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
In Depth 27 Jun 2024 The 2024 drug approval list: Eight new treatments you should know about …bleeding rate (ABR) – a measure for the number of reported bleeding events – of 2.5 was observed among patients who received BEQVEZ in the efficacy evaluation period compared to… June 27, 2024 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 16 Dec 2019 Amarin’s Triglyceride-Lowering Drug Gets Second FDA Nod to Tackle Cardiovascular Disease …more patients. The latest approval comes after a phase III trial in 8,000 patients in which Vascepa cut the risk of cardiovascular events by an impressive 25% compared to a… December 16, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email